Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Iovance Biotherapeutics, Inc. (IOVA : NSDQ)
 
 • Company Description   
Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.

Number of Employees: 319

 
 • Price / Volume Information   
Yesterday's Closing Price: $15.43 Daily Weekly Monthly
20 Day Moving Average: 1,900,694 shares
Shares Outstanding: 157.17 (millions)
Market Capitalization: $2,425.10 (millions)
Beta: 0.86
52 Week High: $28.00
52 Week Low: $11.91
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.98% 8.13%
12 Week 3.91% 14.22%
Year To Date -19.17% -4.31%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
825 INDUSTRIAL ROAD SUITE 400
-
SAN CARLOS,CA 94070
USA
ph: 650-260-7120
fax: -
sara.pellegrino@iovance.com http://www.iovance.com
 
 • General Corporate Information   
Officers
Frederick G. Vogt - Interim Chief Executive Officer and President; and
Jean-Marc Bellemin - Chief Financial Officer and Treasurer
Merrill A. McPeak - Director
Michael Weiser - Director
Ryan D. Maynard - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 462260100
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 157.17
Most Recent Split Date: 9.00 (0.01:1)
Beta: 0.86
Market Capitalization: $2,425.10 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.45 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.39
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -13.73%
vs. Previous Quarter: 7.94%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -54.79
12/31/21 - -50.48
09/30/21 - -45.34
ROA
03/31/22 - -45.37
12/31/21 - -42.65
09/30/21 - -38.91
Current Ratio
03/31/22 - 6.36
12/31/21 - 5.69
09/30/21 - 9.00
Quick Ratio
03/31/22 - 6.36
12/31/21 - 5.69
09/30/21 - 9.00
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 3.51
12/31/21 - 3.96
09/30/21 - 4.45
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.18
12/31/21 - 0.16
09/30/21 - 0.14
 

Powered by Zacks Investment Research ©